eFT226 + Sotorasib + Fulvestrant + Abemaciclib + Trastuzumab
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor, Adult
Conditions
Solid Tumor, Adult
Trial Timeline
Oct 25, 2019 → Mar 31, 2025
NCT ID
NCT04092673About eFT226 + Sotorasib + Fulvestrant + Abemaciclib + Trastuzumab
eFT226 + Sotorasib + Fulvestrant + Abemaciclib + Trastuzumab is a phase 1/2 stage product being developed by eFFECTOR Therapeutics for Solid Tumor, Adult. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04092673. Target conditions include Solid Tumor, Adult.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04092673 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Solid Tumor, Adult